NPS Pharmaceuticals, Inc.  

(Public, NASDAQ:NPSP)   Watch this stock  
Find more results for NPSP
23.38
-0.12 (-0.51%)
Apr 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 22.11 - 24.30
52 week 11.65 - 39.68
Open 23.63
Vol / Avg. 3.42M/2.07M
Mkt cap 2.41B
P/E     -
Div/yield     -
EPS -0.15
Shares 103.26M
Beta 0.17
Inst. own 96%
May 7, 2014
Q1 2014 NPS Pharmaceuticals Earnings Release (Estimated) Add to calendar
May 6, 2014
NPS Pharmaceuticals Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
Apr 8, 2014
NPS Pharmaceuticals at Needham Life Sciences Conference - Webcast
Mar 11, 2014
NPS Pharmaceuticals at Barclays Healthcare Conference - Webcast
Feb 25, 2014
NPS Pharmaceuticals at Citi Global Healthcare Conference
Feb 24, 2014
NPS Pharmaceuticals at Canaccord Genuity Orphan Drug One-on-One Day
Feb 18, 2014
Q4 2013 NPS Pharmaceuticals Earnings Conference Call - Webcast
Feb 18, 2014
Q4 2013 NPS Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 14.27% -8.68%
Operating margin 19.45% -0.96%
EBITD margin - 0.73%
Return on average assets 10.95% -6.09%
Return on average equity 31.68% -53.75%
Employees 207 -
CDP Score - -

Address

550 HILLS DRIVE
BEDMINSTER, NJ 07921
United States - Map
+1-908-4505300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company�s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food and Drug Administration (FDA) during the year ended December 31, 2012, for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Natpara is the recombinant full-length human parathyroid hormone (rhPTH (1-84)), which is developing as a hormone replacement therapy for hypoparathyroidism, a rare hormone deficiency disorder, in which patients are physiologically unable to regulate the levels of calcium and phosphates in their blood due to insufficient levels of endogenous parathyroid hormone (PTH).

Officers and directors

Peter G. Tombros Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Francois Nader M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Luke M. Beshar CPA Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Christine Mikail Senior Vice President - Legal Affairs, General Counsel
Bio & Compensation  - Reuters
Glenn R. Melrose Senior Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Roger J. Garceau M.D. Chief Medical Officer, Senior Vice President
Age: 59
Bio & Compensation  - Reuters
Eric Pauwels Chief Commercial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Joseph J. Rogus Vice President - Technical Operations and Supply Chain Management
Age: 66
Bio & Compensation  - Reuters
Michael W. Bonney Independent Director
Age: 54
Bio & Compensation  - Reuters
Colin Broom M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters